Treatment of Chronic Active Antibody Mediated Rejection With Tocilizumab

Launched by SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES · May 27, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the use of a medication called tocilizumab to treat a specific type of kidney transplant rejection known as chronic active antibody-mediated rejection (CAMR). CAMR is a serious condition that can occur in kidney transplant patients and is difficult to treat with standard therapies. The trial aims to see if tocilizumab can help improve kidney function and increase the chances of the transplant lasting longer, as currently, about 5,000 kidney transplants are lost each year in the U.S. due to CAMR.

To be eligible for this trial, participants need to be between the ages of 65 and 74, have a specific level of kidney function, and show signs of antibody-mediated rejection. They must also be free from active infections and certain other health issues. Those who join the study will receive tocilizumab and will be monitored closely to see how their kidneys respond. This trial is an important step in finding better treatments for patients dealing with the challenges of CAMR.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Signed written informed consent
• • 2. eGFR\> 25 cc/min
• • 3. Chronicity index \<8
• • 4. IFTA\<40%
• • 5. EBV IgG positive
• Exclusion Criteria:
• • 1. Active or recurrent infections
• • 2. History of malignancy, unless in remission for more than 2 years with no relapse
• • 3. abnormal liver function tests
• • 4. Platelet \< 100,000